SEARCH

Contact Information

sally.qin​@FaegreBD.com

Suite 2702, Park Place
1601 Nanjing Road West

Shanghai 200040, China

D: +86 21 6171 6649
F: +86 21 6171 6501

Education

University of Chicago
LL.M. (2010)
Fudan University
LL.M. (2006)
Shanghai International Studies University
B.A. (2003)

Bar Admissions

New York

Languages

Chinese English

Sally Qin

Associate

Sally Qin joined Faegre Baker Daniels in 2006. Her practice focuses on China-related foreign investment matters, including China market entry strategy, due diligence, formation and operation of onshore wholly owned subsidiaries and joint ventures, cross-border M&A, and general Chinese corporate matters. Sally has advised dozens of U.S. companies on the establishment of their legal presences in China and operational regulatory matters, as well as liquidations and dissolutions.

Transactions Sally has been involved in include the following:

  • Representation of a Fortune 500 company in its US $70 million acquisition of a PRC-based telecommunication company
  • Representation of a leading U.S. auto parts manufacturer in its negotiation on equity joint venture terms with a subsidiary of Dong Feng Motor Corporation
  • Representation of a leading U.S. interventional medical device company in its proposed acquisition of a Hong Kong company with PRC operations
  • Representation of the nominated advisor on the proposed AIM listing by a PRC-based company which operates a network of 20 department stores in eight provinces
  • Representation of a U.S. private equity fund in its proposed investment in a PRC-based company which operates an online B2B trading platform
  • Representation of a PRC-based pharmaceutical company in its US $50 million series B financing with shares purchased by a syndicate of venture capital investment funds

Published Articles

  • An Update on China's Cybersecurity Law, 3 Months In
    Co-author, Law360, September 2017

DISCLAIMER

Transmission of information to us via this feature does not establish an attorney-client relationship. Do not send any information that you would have treated confidentially.